Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

A project funded by the United States Agency for International Development (USAID) has made significant contributions to ...

Alchemy, a developer of in-house pharmacy programs for clinics with large HIV and hepatitis C patient populations, raised $31 ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

The following is a summary of “Drug-drug interactions between antiretrovirals and hormonal contraception: An updated ...

7 October 2024 (Lima, Peru) – New data from the PURPOSE 2 study of twice-yearly lenacapavir for HIV prevention are among the scientific highlights at HIVR4P 2024, the 5th HIV Research for Prevention ...

Access to antiretrovirals has expanded dramatically. In South Africa, 6.1 out of 7.9 million people living with HIV are on antiretrovirals. Today, most adults living with HIV in sub-Saharan Africa ...

The pacts will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to prevent HIV through pre-exposure prophylaxis ...